Neuropeptide Y receptor: Difference between revisions
Jump to navigation
Jump to search
m (Moving from Category:G protein coupled receptors to Category:G protein-coupled receptors using Cat-a-lot) |
Matt Pijoan (talk | contribs) m (1 revision imported) |
(No difference)
| |
Latest revision as of 11:53, 10 January 2019
| neuropeptide Y receptor Y1 | |
|---|---|
| Identifiers | |
| Symbol | NPY1R |
| Alt. symbols | NPYR |
| Entrez | 4886 |
| HUGO | 7956 |
| OMIM | 162641 |
| RefSeq | NM_000909 |
| UniProt | P25929 |
| Other data | |
| Locus | Chr. 4 q31.3-q32 |
| neuropeptide Y receptor Y2 | |
|---|---|
| Identifiers | |
| Symbol | NPY2R |
| Entrez | 4887 |
| HUGO | 7957 |
| OMIM | 162642 |
| RefSeq | NM_000910 |
| UniProt | P49146 |
| Other data | |
| Locus | Chr. 4 q31 |
| pancreatic polypeptide receptor 1 | |
|---|---|
| Identifiers | |
| Symbol | PPYR1 |
| Alt. symbols | NPY4R, Y4, PP1 |
| Entrez | 5540 |
| HUGO | 9329 |
| OMIM | 601790 |
| RefSeq | NM_005972 |
| UniProt | P50391 |
| Other data | |
| Locus | Chr. 10 q11.2 |
| neuropeptide Y receptor Y5 | |
|---|---|
| Identifiers | |
| Symbol | NPY5R |
| Entrez | 4889 |
| HUGO | 7958 |
| OMIM | 602001 |
| RefSeq | NM_006174 |
| UniProt | Q15761 |
| Other data | |
| Locus | Chr. 4 q31-q32 |
Neuropeptide Y receptors are a family of receptors belonging to class A G-protein coupled receptors and they are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.[2][3][4][5][6][7]
Activated neuropeptide receptors release the Gi subunit from the heterotrimeric G protein complex. The Gi subunit in turn inhibits the production of the second messenger cAMP from ATP.
Only the crystal structure of Y1 in complex with two antagonist is available.[8]
Types
There are five known mammalian neuropeptide Y receptors designated Y1 through Y5.[9] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.[10][11][12]
Antagonists
References
- ↑ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761.
- ↑ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides. 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373.
- ↑ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids. 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800.
- ↑ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry. 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774.
- ↑ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery. 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213.
- ↑ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry. 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780.
- ↑ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.
- ↑ Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G, Plank N, Littmann T, Schmidt P, Yi C, Li B, Ye S, Zhang R, Xu B, Larhammar D, Stevens RC, Huster D, Meiler J, Zhao Q, Beck-Sickinger AG, Buschauer A, Wu B (April 2018). "1 receptor". Nature. 556 (7702): 520–524. doi:10.1038/s41586-018-0046-x. PMC 5920736. PMID 29670288.
- ↑ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides. 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367.
- ↑ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews. 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.
- ↑ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry. 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781.
- ↑ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry. 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782.
External links
- "Neuropeptide Y Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
- Neuropeptide+Y+Receptor at the US National Library of Medicine Medical Subject Headings (MeSH)
 | This transmembrane receptor-related article is a stub. You can help Wikipedia by expanding it. |